A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65
← catalyst calendarNCT07060885 · readout in 18 d
Sponsored by ALK-Abelló A/S (industry) · ALK-B.CO — their whole pipeline →. With Changchun GeneScience Pharmaceutical Co., Ltd..
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
327actual
Sites
30
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-01 | actual | When the study began enrolling |
| Primary completion | 2026-09-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-13 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Allergic Rhinoconjunctivitis
- Allergic Rhinitis
Interventions
- Biological: HDM SLIT-tablet (12 SQ-HDM)
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFAverage daily total combined rhinitis score (TCRS) during the primary efficacy assessment period.
measured 4 weeks (primary efficacy assessment period), starting 24 weeks after initiation of IMP.
Permalink · ALK-B.CO's whole pipeline · Catalyst calendar · Every registered study · What changed